United Pharm (033270) - Net Assets

Latest as of December 2025: ₩454.63 Billion KRW ≈ $308.10 Million USD

Based on the latest financial reports, United Pharm (033270) has net assets worth ₩454.63 Billion KRW (≈ $308.10 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩519.49 Billion ≈ $352.05 Million USD) and total liabilities (₩64.86 Billion ≈ $43.96 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 033270 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩454.63 Billion
% of Total Assets	87.51%
Annual Growth Rate	10.45%
5-Year Change	51.19%
10-Year Change	156.29%
Growth Volatility	3.16

United Pharm - Net Assets Trend (2011–2025)

This chart illustrates how United Pharm's net assets have evolved over time, based on quarterly financial data. Also explore 033270 current and non-current assets for the complete picture of this company's asset base.

Annual Net Assets for United Pharm (2011–2025)

The table below shows the annual net assets of United Pharm from 2011 to 2025. For live valuation and market cap data, see 033270 market cap.

Year	Net Assets	Change
2025-12-31	₩454.63 Billion ≈ $308.10 Million	+11.92%
2024-12-31	₩406.21 Billion ≈ $275.28 Million	+7.27%
2023-12-31	₩378.68 Billion ≈ $256.63 Million	+12.08%
2022-12-31	₩337.86 Billion ≈ $228.96 Million	+12.35%
2021-12-31	₩300.71 Billion ≈ $203.79 Million	+8.60%
2020-12-31	₩276.89 Billion ≈ $187.65 Million	+8.54%
2019-12-31	₩255.10 Billion ≈ $172.88 Million	+11.65%
2018-12-31	₩228.48 Billion ≈ $154.84 Million	+13.29%
2017-12-31	₩201.68 Billion ≈ $136.68 Million	+13.70%
2016-12-31	₩177.39 Billion ≈ $120.21 Million	+9.61%
2014-12-31	₩161.83 Billion ≈ $109.67 Million	+14.42%
2013-12-31	₩141.44 Billion ≈ $95.85 Million	+5.96%
2012-12-31	₩133.48 Billion ≈ $90.46 Million	+18.08%
2011-12-31	₩113.04 Billion ≈ $76.61 Million	--

Equity Component Analysis

This analysis shows how different components contribute to United Pharm's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 361.7% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	₩433.06 Billion	95.26%
Other Components	₩21.57 Billion	4.74%
Total Equity	₩454.63 Billion	100.00%

United Pharm Competitors by Market Cap

The table below lists competitors of United Pharm ranked by their market capitalization.

Company	Market Cap
Quang Viet Enterprise Co Ltd TW:4438	$197.72 Million
SNS KLSE:0259	$197.74 Million
Ceragon Networks Ltd NASDAQ:CRNT	$197.76 Million
Samyoung Elec KO:005680	$197.81 Million
Catella AB (publ) ST:CAT-B	$197.61 Million
i-SENS Inc KQ:099190	$197.36 Million
Atomera Inc NASDAQ:ATOM	$197.35 Million
Aurora Cannabis Inc NASDAQ:ACB	$197.35 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in United Pharm's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 406,207,015,510 to 454,629,301,390, a change of 48,422,285,880 (11.9%).
Net income of 38,308,011,300 contributed positively to equity growth.
Dividend payments of 6,620,071,050 reduced retained earnings.
Share repurchases of 5,566,770,850 reduced equity.
New share issuances of 10,407,712,500 increased equity.
Other factors increased equity by 11,893,403,980.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	₩38.31 Billion	+8.43%
Dividends Paid	₩6.62 Billion	-1.46%
Share Repurchases	₩5.57 Billion	-1.22%
Share Issuances	₩10.41 Billion	+2.29%
Other Changes	₩11.89 Billion	+2.62%
Total Change	₩-	11.92%

Book Value vs Market Value Analysis

This analysis compares United Pharm's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.64x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has decreased from 1.48x to 0.64x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	₩13621.84	₩20200.00	x
2018-12-31	₩15431.99	₩20200.00	x
2019-12-31	₩17201.26	₩20200.00	x
2020-12-31	₩18654.34	₩20200.00	x
2021-12-31	₩20258.97	₩20200.00	x
2022-12-31	₩22970.86	₩20200.00	x
2023-12-31	₩25897.56	₩20200.00	x
2024-12-31	₩27611.96	₩20200.00	x
2025-12-31	₩31480.46	₩20200.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently United Pharm utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 8.43%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 13.27%
• Asset Turnover: 0.56x
• Equity Multiplier: 1.14x
Recent ROE (8.43%) is below the historical average (11.62%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2011	17.88%	13.89%	0.86x	1.50x	₩8.90 Billion
2012	12.27%	12.15%	0.72x	1.41x	₩3.03 Billion
2013	8.63%	8.92%	0.71x	1.37x	₩-1.93 Billion
2014	11.35%	11.84%	0.71x	1.34x	₩2.19 Billion
2016	11.00%	11.03%	0.76x	1.32x	₩1.78 Billion
2017	13.82%	14.14%	0.74x	1.32x	₩7.70 Billion
2018	13.86%	14.94%	0.70x	1.32x	₩8.82 Billion
2019	12.12%	13.97%	0.67x	1.30x	₩5.41 Billion
2020	9.61%	12.32%	0.61x	1.28x	₩-1.08 Billion
2021	9.53%	12.96%	0.58x	1.26x	₩-1.42 Billion
2022	13.40%	17.25%	0.63x	1.24x	₩11.49 Billion
2023	12.74%	17.30%	0.59x	1.24x	₩10.39 Billion
2024	7.99%	11.24%	0.61x	1.17x	₩-8.17 Billion
2025	8.43%	13.27%	0.56x	1.14x	₩-7.15 Billion

Industry Comparison

This section compares United Pharm's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $401,390,357,055
Average return on equity (ROE) among peers: 0.79%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
United Pharm (033270)	₩454.63 Billion	17.88%	0.14x	$197.70 Million
Dongwha Pharm.Co.Ltd (000020)	$252.93 Billion	10.38%	0.28x	$113.83 Million
Yuhan Corp. (000100)	$407.93 Billion	10.79%	0.55x	$4.57 Billion
Yuhan Corp Preferred (000105)	$1.65 Trillion	2.42%	0.28x	$59.61 Million
Yuyu Pharma (000220)	$69.50 Billion	3.97%	0.28x	$46.55 Million
Yuyu Pharma Inc (000225)	$117.04 Billion	1.10%	0.32x	$17.67 Million
Yuyu Pharma Inc (000227)	$78.29 Billion	7.52%	0.42x	$42.93 Million
Ildong Holdings Co Ltd (000230)	$169.10 Billion	-60.53%	4.10x	$76.14 Million
Samil Pharm (000520)	$127.83 Billion	1.30%	1.90x	$127.90 Million
Donga Socio Holdings (000640)	$875.86 Billion	17.02%	0.60x	$427.15 Million
Jw Pharmac (001060)	$265.44 Billion	13.94%	1.43x	$476.78 Million

About United Pharm

KO:033270 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$197.70 Million

₩291.72 Billion KRW

Market Cap Rank

#16576 Global

#704 in Korea

Share Price

₩20200.00

Change (1 day)

-1.70%

52-Week Range

₩18130.00 - ₩22350.00

All Time High

₩95918.11